Abstract
The proteins Ure2, Sup35 and Rnq1 from the bakers yeast have infectious properties, termed prions, at the origin of heritable and transmissible phenotypic changes. It is widely believed that prion properties arise from the assembly of Ure2p, Sup35p and Rnq1p into insoluble fibrils. Yeast prions possess regions crucial for their propagation that can be either N- or C-terminal. These regions have unusual amino acid composition. They are very rich in glutamine and asparagine residues and resemble in that to huntingtin, a protein involved in the neurodegenerative Huntingtons disease. Yeast prions assembly process has been hypothesized to be the consequence of the properties of glutamines and asparagines to engage in polar protein-protein interactions, termed polar-zippers. While this can certainly occur under certain conditions, glutamine and asparagine residues can establish other kinds of interactions with a variety of amino acid residues thus mediating protein-protein interactions involved in the assembly of polypeptide chains into high molecular weight oligomers. This review details the interactions that can be established by glutamine and asparagine residues that may allow a better understanding of their role in mediating protein-protein interactions and prion propagation.
Keywords: Prion, [PSI+], [URE3], Sup35p, Ure2p, amyloid fibrils, native-like assemblies
Current Alzheimer Research
Title: Assembly of the Asparagine- and Glutamine-Rich Yeast Prions into Protein Fibrils
Volume: 5 Issue: 3
Author(s): Luc Bousset, Jimmy Savistchenko and Ronald Melki
Affiliation:
Keywords: Prion, [PSI+], [URE3], Sup35p, Ure2p, amyloid fibrils, native-like assemblies
Abstract: The proteins Ure2, Sup35 and Rnq1 from the bakers yeast have infectious properties, termed prions, at the origin of heritable and transmissible phenotypic changes. It is widely believed that prion properties arise from the assembly of Ure2p, Sup35p and Rnq1p into insoluble fibrils. Yeast prions possess regions crucial for their propagation that can be either N- or C-terminal. These regions have unusual amino acid composition. They are very rich in glutamine and asparagine residues and resemble in that to huntingtin, a protein involved in the neurodegenerative Huntingtons disease. Yeast prions assembly process has been hypothesized to be the consequence of the properties of glutamines and asparagines to engage in polar protein-protein interactions, termed polar-zippers. While this can certainly occur under certain conditions, glutamine and asparagine residues can establish other kinds of interactions with a variety of amino acid residues thus mediating protein-protein interactions involved in the assembly of polypeptide chains into high molecular weight oligomers. This review details the interactions that can be established by glutamine and asparagine residues that may allow a better understanding of their role in mediating protein-protein interactions and prion propagation.
Export Options
About this article
Cite this article as:
Bousset Luc, Savistchenko Jimmy and Melki Ronald, Assembly of the Asparagine- and Glutamine-Rich Yeast Prions into Protein Fibrils, Current Alzheimer Research 2008; 5 (3) . https://dx.doi.org/10.2174/156720508784533303
DOI https://dx.doi.org/10.2174/156720508784533303 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Influence of Different Substituents on Anion Binding Ability in Aromatic Hydroxyl Group Derivatives: Experiment and Theory
Current Analytical Chemistry Cyclic Opioid Peptides
Current Medicinal Chemistry Metal Triflates: Efficient Catalysts for Oxa-Pictet-Spengler Reaction
Letters in Organic Chemistry Meet Our Editorial Board Member
Current Neuropharmacology Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) In-hospital Falls in Older Patients: The Risk Factors and The Role of Hyponatraemia
Current Aging Science The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration
Current Neuropharmacology Editorial (Cellular Senescence and Inflammation: Advances and Therapeutic Targets in Aging and Major Age-Related Diseases)
Current Pharmaceutical Design Evidence of Nestin-Positive Cells in the Human Cutaneus Meissner and Pacinian Corpuscles
CNS & Neurological Disorders - Drug Targets Chronic Myelogenous Leukemia
Current Cancer Therapy Reviews Update on the Medical Treatment of Allergic Rhinitis
Inflammation & Allergy - Drug Targets (Discontinued) Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Combining Growth Factor and Stem Cell Therapy for Stroke Rehabilitation, A Review
Current Drug Targets The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets New Perspectives in the Treatment of Cushings Syndrome
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Autophagy to the Rescue
Current Neurovascular Research In Silico Prediction of P-glycoprotein Binding: Insights from Molecular Docking Studies
Current Medicinal Chemistry Regional Cerebral Blood Flow and Cerebrovascular Reactivity in Alzheimer’s Disease and Vascular Dementia Assessed by Arterial Spinlabeling Magnetic Resonance Imaging
Current Neurovascular Research Gamma-Amino Butyric Acid Inhibits the Nicotine-Imposed Stimulatory Challenge in Xenograft Models of Non-Small Cell Lung Carcinoma
Current Cancer Drug Targets Addressing Crises in Teenage Pregnancy
Adolescent Psychiatry